INDICATORS ON SHIELD-1 YOU SHOULD KNOW

There have been no clinically considerable differences from the pharmacokinetics of either midazolam (CYP3A4 substrate) or repaglinide (CYP2C8 substrate) when used concomitantly with finerenone. A number of doses of 40 mg finerenone once-everyday had no clinically relevant effect on AUC or Cmax from the BCRP and OATP substrate rosuvastatin.ketocona